Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Prior Acute Myocardial Infarction Clear all

Completed Phase 3 Interventional Results available

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

NCT00046228

View directory record Official record

Conditions: Myocardial Infarction
Interventions: abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 21 Years and older

Enrollment: 2,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 52
States / cities: Phoenix, Arizona • Covina, California • Modesto, California + 49 more

Source: ClinicalTrials.gov public record

Updated Jul 30, 2014 · Synced May 22, 2026, 4:12 AM EDT

Terminated Phase 2 Interventional

Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients

NCT01655433

View directory record Official record

Conditions: ST-elevation MI, Hypothermia
Interventions: Velomedix APLS device, No Hypothermia Treatment; Device · Other
Lead sponsor: Velomedix, Inc.; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Huntsville, Alabama • Los Angeles, California • Gainesville, Georgia + 2 more

Source: ClinicalTrials.gov public record

Updated Jul 24, 2014 · Synced May 22, 2026, 4:12 AM EDT

Completed Phase 3 Interventional Results available

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562

View directory record Official record

Conditions: Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions: Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years

Enrollment: 21,379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 250
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more

Source: ClinicalTrials.gov public record

Updated Jan 24, 2016 · Synced May 22, 2026, 4:12 AM EDT

Completed No phase listed Observational

Hemorrhagic MI Prediction Score Model

NCT06423625

View directory record Official record

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Rohan Dharmakumar; Other
Eligibility: 18 Years to 79 Years

Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Source: ClinicalTrials.gov public record

Updated Jan 5, 2026 · Synced May 22, 2026, 4:12 AM EDT

Recruiting Phase 2 Interventional

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739

View directory record Official record

Conditions: Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
Interventions: Orticumab, Placebo; Drug
Lead sponsor: Abcentra; Industry
Eligibility: 18 Years and older

Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Torrance, California • Boca Raton, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated Jan 26, 2026 · Synced May 22, 2026, 4:12 AM EDT

Completed Not applicable Interventional

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

NCT01900600

View directory record Official record

Conditions: Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
Interventions: Cardiopulmonary exercise test, Echocardiogram; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 110 Years

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Source: ClinicalTrials.gov public record

Updated Oct 9, 2018 · Synced May 22, 2026, 4:12 AM EDT

Terminated Phase 4 Interventional

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

NCT00168792

View directory record Official record

Conditions: Myocardial Infarction
Interventions: Tenecteplase, PCI; Drug · Procedure
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 1,671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Little Rock, Arkansas • Fort Lauderdale, Florida • St. Petersburg, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Oct 28, 2013 · Synced May 22, 2026, 4:12 AM EDT